Organon & Co. $OGN Shares Acquired by Brandes Investment Partners LP

Brandes Investment Partners LP grew its stake in Organon & Co. (NYSE:OGN) by 77.1% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 398,423 shares of the company’s stock after acquiring an additional 173,481 shares during the period. Brandes Investment Partners LP owned about 0.15% of Organon & Co. worth $3,857,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently made changes to their positions in the stock. GAMMA Investing LLC increased its holdings in Organon & Co. by 22.4% in the 2nd quarter. GAMMA Investing LLC now owns 5,645 shares of the company’s stock valued at $55,000 after purchasing an additional 1,034 shares during the last quarter. Maryland State Retirement & Pension System grew its stake in shares of Organon & Co. by 1.4% in the second quarter. Maryland State Retirement & Pension System now owns 88,420 shares of the company’s stock valued at $856,000 after buying an additional 1,195 shares in the last quarter. Allworth Financial LP raised its holdings in shares of Organon & Co. by 65.9% in the 2nd quarter. Allworth Financial LP now owns 4,501 shares of the company’s stock valued at $44,000 after buying an additional 1,788 shares during the period. Yousif Capital Management LLC lifted its stake in Organon & Co. by 2.3% during the 2nd quarter. Yousif Capital Management LLC now owns 79,975 shares of the company’s stock worth $774,000 after acquiring an additional 1,789 shares in the last quarter. Finally, Hantz Financial Services Inc. lifted its stake in Organon & Co. by 293.8% during the 2nd quarter. Hantz Financial Services Inc. now owns 2,674 shares of the company’s stock worth $26,000 after acquiring an additional 1,995 shares in the last quarter. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on OGN. JPMorgan Chase & Co. cut their price target on shares of Organon & Co. from $14.00 to $12.00 and set an “underweight” rating on the stock in a research note on Tuesday, November 11th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Organon & Co. in a research note on Wednesday, October 8th. Morgan Stanley reduced their target price on shares of Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating on the stock in a report on Tuesday, November 11th. Finally, Piper Sandler downgraded shares of Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 price target for the company. in a research note on Monday, October 27th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have issued a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $12.50.

Organon & Co. Trading Down 1.5%

NYSE OGN opened at $7.49 on Wednesday. Organon & Co. has a 52 week low of $6.18 and a 52 week high of $17.23. The firm has a 50 day moving average of $8.47 and a two-hundred day moving average of $9.26. The company has a quick ratio of 1.20, a current ratio of 1.75 and a debt-to-equity ratio of 9.69. The stock has a market capitalization of $1.95 billion, a PE ratio of 3.90, a price-to-earnings-growth ratio of 1.63 and a beta of 0.57.

Organon & Co. (NYSE:OGN) last released its quarterly earnings data on Monday, November 10th. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.93 by $0.08. The business had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Organon & Co. had a net margin of 7.95% and a return on equity of 143.47%. During the same period in the previous year, the company earned $1.38 EPS. As a group, research analysts expect that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 11th. Stockholders of record on Thursday, November 20th will be given a dividend of $0.02 per share. This represents a $0.08 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Thursday, November 20th. Organon & Co.’s dividend payout ratio is currently 4.17%.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.